The CD14+HLA-DRlo/neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy

Immunotherapy

The Unfolded Protein Response in Immunogenic Cell Death and Cancer Immunotherapy

Trends Cancer.

Rufo N, Garg AD, Agostinis P

doi: 10.1016/j.trecan.2017.07.002.

Melanoma and Skin CancerImmunotherapy

Identification of essential genes for cancer immunotherapy

Nature.

Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP

doi: 10.1038/nature23477.

Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy

Crit Rev Oncol Hematol.

Solinas C, Porcu M, Hlavata Z, De Silva P, Puzzoni M, Willard-Gallo K, Scartozzi M, Saba L

doi: 10.1016/

T Cells

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Semin Cancer Biol.

Kumar P, Saini S, Prabhakar BS

doi: 10.1016/j.semcancer.

Melanoma and Skin CancerImmunotherapy

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

Nat Med.

Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B

doi: 10.1038/nm.4466.

Immunotherapy

Immunotherapy in Gastrointestinal Cancers

Biomed Res Int.

Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A, Zagonel V, Lonardi S

doi: 10.1155/2017/4346576.

Immunotherapy

Novel immunotherapy strategies for hepatobiliary cancers

Immunotherapy.

DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ

doi: 10.2217/imt-2018-0024.

Melanoma and Skin Cancer

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

Lancet Oncol.

Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, Wong YNS, Rowan A, Kanu N, Al Bakir M, Chambers T, Salgado R, Savas P, Loi S, Birkbak NJ, Sansregret L, Gore M, Larkin J, Quezada SA, Swanton C

doi: 10.1016/

Immunotherapy

Recent progress in therapeutic antibodies for cancer immunotherapy

doi: 10.1016/j.cbpa.2018.05.006.

Related content

The Unfolded Protein Response in Immunogenic Cell Death and Cancer Immunotherapy

Identification of essential genes for cancer immunotherapy

Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

Immunotherapy in Gastrointestinal Cancers

Novel immunotherapy strategies for hepatobiliary cancers

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

Recent progress in therapeutic antibodies for cancer immunotherapy